Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Relapsed Follicular Non-Hodgkin's Lymphoma
NCT00004179Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 1999
- Primary completion
- Apr 2004
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of rituximab in follicular lymphoma (FL) (4 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Response to treatment and Quality of remission. Started May 1999; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00004179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004179.